Tonix Pharmaceuticals Holding Corp. Stock





Market Closed - Nasdaq 04:00:00 2024-06-18 pm EDT 5-day change 1st Jan Change
1.22 USD +8.93% Intraday chart for Tonix Pharmaceuticals Holding Corp. -42.72% -90.54%
Sales 2024 * 13.92M Sales 2025 * 17.78M Capitalization 4.69M
Net income 2024 * -79M Net income 2025 * -91M EV / Sales 2024 * 0.34 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.26 x
P/E ratio 2024 *
-0.04 x
P/E ratio 2025 *
-0.06 x
Employees 103
Yield 2024 *
Yield 2025 *
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Top Midday Decliners MT
Wall Street Set to Open Higher Wednesday as Key Inflation Data Lower Than Expected MT
US Futures Slightly Higher Ahead of Fed's Rate Decision, Key Inflation Data MT
Top Premarket Decliners MT
Tonix Pharmaceuticals Plans Common Stock Offering to Fund New Drug Application for Fibromyalgia; Shares Fall After Hours MT
Tonix Pharmaceuticals to Implement 1-for-32 Reverse Stock Split -- Shares Fall MT
Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 CI
ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tonix Pharmaceuticals Prices $4.4 Million Direct Offering; Revises Existing Warrant Terms -- Shares Tumble MT
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome MT
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting CI
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial CI
More news
1 day+8.93%
1 week-44.80%
Current month-76.60%
1 month-80.67%
3 months-88.12%
6 months-93.33%
Current year-90.54%
More quotes
1 week
Extreme 1.08
1 month
Extreme 1.08
Current year
Extreme 1.08
1 year
Extreme 1.08
3 years
Extreme 1.08
8 256.00
5 years
Extreme 1.08
104 332.80
10 years
Extreme 1.08
1 000 000.00
More quotes
Date Price Change Volume
24-06-18 1.22 +8.93% 1,710,271
24-06-17 1.12 -2.61% 1,282,398
24-06-14 1.15 +5.50% 6,682,590
24-06-13 1.09 -1.80% 2,106,216
24-06-12 1.11 -47.89% 5,182,178

Delayed Quote Nasdaq, June 18, 2024 at 04:00 pm EDT

More quotes
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
1.12 USD
Average target price
94.93 USD
Spread / Average Target